Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges

This report aims to review criteria which have been proposed for treatment evaluation in mRCC under anti-angiogenic and immune-oncologic therapies and discuss future challenges for imagers. RECIST criteria seem to only partially reflect the clinical benefit derived from anti-angiogenic drugs in mRCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Fournier, Laure, Bellucci, Alexandre, Vano, Yann, Bouaboula, Mehdi, Thibault, Constance, Elaidi, Reza, Oudard, Stephane, Cuenod, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179123/
https://www.ncbi.nlm.nih.gov/pubmed/30334012
http://dx.doi.org/10.3233/KCA-170011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179123/
https://www.ncbi.nlm.nih.gov/pubmed/30334012
http://dx.doi.org/10.3233/KCA-170011

Ejemplares similares